View Older Stories View More Recent Stories

Apr 7, 2026 05:44AM Viridian Therapeutic (VRDN) PT Lowered to $30 at RBC Capital
Apr 6, 2026 06:01PM Viridian Therapeutic (VRDN) PT Lowered to $31 at Goldman Sachs
Apr 6, 2026 01:12PM Leerink Partners on Viridian Therapeutic (VRDN): share weakness on AMGN results 'overdone'
Apr 6, 2026 11:45AM RBC: 'we expect to see a negative impact to VRDN's shares', Shares 24% Today
Apr 6, 2026 09:46AM Stifel on Viridian (VRDN): 'We view positive REVEAL-2 chronic TED data in 2Q26 as important'
Apr 2, 2026 05:14AM Viridian Therapeutic (VRDN) PT Lowered to $32 at Evercore ISI
Mar 31, 2026 06:39AM Viridian Therapeutic (VRDN) PT Lowered to $22 at H.C. Wainwright
Mar 31, 2026 05:34AM Viridian Therapeutic (VRDN) PT Lowered to $29 at Wolfe Research
Mar 30, 2026 01:02PM Viridian Therapeutic (VRDN) PT Lowered to $29 at Jefferies
Mar 30, 2026 09:19AM Stifel on Viridian Therapeutic (VRDN): data 'disappointing at face,' but Elegrobart still potentially BIC
Mar 30, 2026 08:46AM Truist Securities on Viridian Therapeutic (VRDN): data places SC Ele' as 'notable therapeutic companion' to IV Veli'
Mar 30, 2026 08:41AM Leerink Partners on Viridian Therapeutic (VRDN): 'encouraged' by response rate, but efficacy below investor expectations
Mar 30, 2026 08:24AM Jefferies on Viridian Therapeutic (VRDN): bears to argue commercial oppy not clean, bulls see de-risk
Mar 18, 2026 09:21AM RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
Feb 26, 2026 05:34PM Viridian Therapeutics, Inc. (VRDN) Tops Q4 EPS by 64c
Feb 26, 2026 02:58PM Stifel on Viridian Therapeutic (VRDN): 'We think shares can trade in the $40+ range'
Feb 26, 2026 10:36AM Viridian Therapeutic (VRDN) PT Raised to $45 at Jefferies
Feb 26, 2026 09:58AM Evercore ISI Adds Viridian Therapeutic (VRDN) to TAP List
Feb 18, 2026 07:51AM Truist on Viridian Therapeutic (VRDN): 'Ele' Positioned to Hit Proptosis Bar'
Jan 28, 2026 06:41AM Viridian Therapeutic (VRDN) PT Raised to $45 at Evercore ISI
Jan 7, 2026 01:03AM UBS Starts Viridian Therapeutic (VRDN) at Buy
Jan 6, 2026 03:14PM TD Cowen on Viridian Therapeutic (VRDN): 'VRDN is a Top Pick'
Jan 6, 2026 03:13PM Jefferies on Viridian Therapeutic (VRDN): 'Attractive 2026 Setup With Pot'l Launch and Pivotal Data', 'one of our Top Picks in 2026'
Jan 6, 2026 07:02AM Viridian gets FDA priority review for thyroid eye disease drug
Dec 23, 2025 09:29AM Truist Sees 'Catalyst-Rich 2026 Set-Up' for Viridian Therapeutic (VRDN)
Dec 22, 2025 07:01AM FDA accepts Viridian Therapeutics' drug application with priority review
Dec 19, 2025 09:06AM TD Cowen on Biotechnology: '10+ Potential "Thome Run" Catalysts To Watch In 2026'
Dec 18, 2025 03:57AM Goldman on Viridian (VRDN): 'believes the market can potentially grow ~2-3x at peak due to veli's and '003's potential to expand use in chronic TED'
Dec 10, 2025 06:53AM Viridian Therapeutic (VRDN) PT Raised to $47 at Wedbush, Adds to BIL
Dec 3, 2025 06:06AM William Blair Starts Viridian Therapeutic (VRDN) at Outperform
Nov 24, 2025 07:33AM Truist Securities Starts Viridian Therapeutic (VRDN) at Buy
Nov 6, 2025 04:26AM Viridian Therapeutic (VRDN) PT Raised to $45 at RBC Capital
Nov 5, 2025 12:06PM Viridian Therapeutic (VRDN) PT Raised to $48 at Stifel
Nov 3, 2025 08:34AM Viridian submits drug application to FDA for thyroid eye disease treatment
Oct 21, 2025 06:47AM H.C. Wainwright Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Sep 16, 2025 05:23AM BTIG Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Sep 15, 2025 07:02AM Viridian completes enrollment in phase 3 thyroid eye disease trials
Sep 5, 2025 07:33AM Viridian Therapeutics (VRDN) files mixed shelf
Aug 25, 2025 07:47AM Jefferies Assumes Viridian Therapeutic (VRDN) at Buy
Aug 6, 2025 06:52AM Viridian Therapeutics, Inc. (VRDN) Reports In-Line Q2 EPS
May 21, 2025 11:36AM B.Riley Reiterates Neutral Rating on Viridian Therapeutic (VRDN)
May 20, 2025 07:01AM Viridian Therapeutics (VRDN) Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
May 7, 2025 04:31PM Viridian Therapeutics (VRDN) Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease
May 6, 2025 09:35AM Stifel on Viridian Therapeutic (VRDN): 'Rapidly Transitioning to Commercial Stage Company'
May 6, 2025 07:33AM Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 11c
Apr 7, 2025 07:00AM Viridian Therapeutics (VRDN) Appoints Jeff Ajer to its Board
Apr 4, 2025 07:58AM Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Feb 27, 2025 07:13AM Viridian Therapeutics, Inc. (VRDN) Tops Q4 EPS by 22c
Jan 7, 2025 08:29AM Stifel Reiterates Buy Rating on Viridian Therapeutic (VRDN)
Dec 17, 2024 09:16AM RBC on Viridian (VRDN): 'Compelling THRIVE-2 Data Could Change the Game for Chronic TED & VRDN'; PT Raised
View More Recent Stories View Older Stories